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Abstract
Over the past decade there have been significant advances in the clinical understanding and care of rheumatoid 
arthritis (RA). Major paradigm changes include earlier disease detection and introduction of therapy, and 'tight control' 
of follow-up driven by regular measurement of disease activity parameters. The advent of tumour necrosis factor (TNF) 
inhibitors and other biologic therapies have further revolutionised care. Low disease state and remission with 
prevention of joint damage and irreversible disability are achievable therapeutic goals. Consequently new 
opportunities exist for all health professionals to contribute towards these advances. For podiatrists relevant issues 
range from greater awareness of current concepts including early referral guidelines through to the application of 
specialist skills to manage localised, residual disease activity and associated functional impairments. Here we describe a 
new paradigm of podiatry care in early RA. This is driven by current evidence that indicates that even in low disease 
activity states destruction of foot joints may be progressive and associated with accumulating disability. The paradigm 
parallels the medical model comprising early detection, targeted therapy, a new concept of tight control of foot 
arthritis, and disease monitoring.
'Podiatrists are experts on foot disorders: both patients and rheumatologists can profit from the involvement of a podiatrist'
- Korda and Balint, 2004 [1].
Early RA
There is no established definition for early rheumatoid
arthritis. Historic criteria for the classification of RA such
as the American College of Rheumatology classification
criteria are based on patients with long-standing disease.
These criteria lack sensitivity in early disease and delay-
ing treatment until patients fulfil such criteria is no lon-
ger acceptable. By symptom duration, the definition of
early RA has progressively shorted from <5 years to <12-
24 months, whilst very early disease indicates the period
within the first 12-16 weeks of symptoms [2]. In practice
early arthritis is often undifferentiated and may go on to
remission, develop into established RA or other form of
arthritis, or remain undifferentiated [3-5]. The imminent
introduction of the new EULAR/ACR diagnostic criteria
for RA will substantially improve matters in the medium
term. Meantime, the clinical challenge in early disease is
to recognise inflammatory arthritis, exclude diseases
other than RA, estimate the risk of patients developing
persistent, erosive, and irreversible disease, and to initiate
therapy and thereafter monitor disease for optimal out-
come [6].
Advances in early RA
Understanding of rheumatoid arthritis has undergone a
revolution in the past two decades in clinical and discov-
ery domains [3]. Notably, concepts of the pathogenesis of
RA have evolved considerably in this period, leading
directly to introduction of biological therapeutics [6]. The
development of an optimal strategic approach includes
the early use of traditional disease-modifying anti-rheu-
matic drugs (DMARDs) and prompt advent of biologic
based interventions in appropriate patients. In conse-
quence, outcomes that can now be achieved are signifi-
cantly advanced. A key message from recent research is
the requirement for rapid recognition and early 'aggres-
sive' intervention. Consider the following evidence, that;
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Page 2 of 10- Ultrasound (US) and magnetic resonance imaging
(MRI) studies demonstrate erosive changes from the
early stages of RA [7-9].
- Functional loss occurs early and once present is
often irreversible [5].
- Mortality rates for RA are increased [10].
- A biological 'window of opportunity' probably exists
whereby intervention can alter the ultimate pathoge-
netic fate for the disease, leading to improved out-
comes [11-14]. This is supported by evidence which
indicates that early introduction of most treatment
modalities is associated with improved clinical
response rates. Early intervention with potent biolog-
ical agents appears to offer profound improvements
in clinical response rates and in the magnitude of ben-
efit. A modest proportion of patients may achieve
subsequent drug free periods of remission. A new
strategy in early RA called 'tight control' aims for
remission and tailors the treatment strategy to indi-
vidual patients' disease activity [15-17]. Tight control
is achieved by regular monitoring using composite,
largely objective disease activity indices, the compo-
nents of which capture both joint damage and func-
tional impairment. Finally, good clinical practice
indicates that it is difficult to justify delay in treating
inflammatory disease once it is recognised.
Foot involvement in early RA
Small joint arthritis is a hallmark feature of early RA and
the feet are frequently involved at onset. Evidence to sup-
port this is taken from prospective and retrospective
cohort studies which estimate the prevalence to be
between 35-70% [18-20]. Prevalence is also high in all
presenting inflammatory arthritis sub-types. In a very
early arthritis cohort of 634 patients with symptoms ≤ 16
weeks duration, the ankle joint (18.9%) was the second
most frequently involved joint after the knee (47.3%) in
those with monoarthritis. In oligoarthritis (2-4 joints
affected) the distribution of joint involvement was also
high for the feet including ankle (43.5%), tarsus (7.9%),
metatarsophalangeal (MTP) joints (18.1%) and toe joints
(6.0%). In those patients with polyarthritis (≥ 5 joints
affected), 50.3% had involvement of the MTP joints,
33.7% the ankle, 17.7% the tarsus and 9.7% the toe joints
[2]. In a cohort of UK RA patients with <2 years duration,
90% of patients had experienced foot pain at some point
of their illness [20].
Synovitis is detected clinically by joint swelling and
effusion. Pain and tenderness indicates soft-tissue and
structural joint damage, the consequence of inflamma-
tion, which is best detected and graded using plain x-ray
or US. In the forefoot, van der Leeden et al (2008) found
that 70% of patients with RA had pain and swelling of at
least one MTP joint at diagnosis, decreasing to between
40-50% after two years with commencement of DMARD
therapy [19]. However, both the prevalence and severity
of forefoot joint damage progressively increased in this
cohort over 8 years of follow up (prevalence 19% at base-
line increasing to 60% and mean forefoot erosion score
1.3 at baseline increasing to 7.9).
Even patients in disease remission (based on the 28
joint count disease activity score - DAS28) may still have
residual active disease in the feet. Discordance between
DAS and DAS28 remission has been attributed to activity
(tenderness and swelling) in the ankle and foot joints [21].
van der Leeden et al (2010) has shown that in 848
patients with recent onset RA, those reaching the DAS28
<2.6 remission criteria, 29% of cases had at least one
painful MTP joint and 31% had at least one swollen MTP
during an eight year follow up [22]. However, Kapral et al
(2007) found higher patient global assessment of disease
activity in patients with swollen and tender foot joints
who were DAS28 inactive, concluding that assessment of
the feet and ankles are important only in the clinical eval-
uation of patients with RA [23]. The reasons for localised
disease persistence in the foot joints are unknown but
mechanical factors have been postulated [24,25].
Retrospective radiographic studies suggest that
involvement of the ankle and tarsus in early disease is rare
with evidence of destructive changes observed in <1% of
cases [26,27]. However, diagnostic MRI and US studies
have been useful in detecting early synovitis in these
joints as well as tendinopathies and bursitides, although
none of these are epidemiological investigations [28-31].
Early involvement of the peritalar joints and tendinopa-
thy of tibialis posterior in particular have been implicated
in development of acquired pes planovalgus [24,32].
Foot associated functional impairment in early RA is
poorly understood. van der Leeden et al (2008) estimated
the prevalence of walking disability in an early arthritis
cohort to be 57% [19]. Case-series data reveal the early
stages of irreversible foot-related walking disability and,
by detailed gait analysis, functional impairment at the
ankle, tarsus and MTP joints [24].
What are the consequences of persistent or residual
active foot disease which is not optimally managed? It is
beyond the scope of this review to consider all the evi-
dence but studies which span the paradigm shift in the
clinical understanding of RA suggest high prevalence,
high burden and an overall negative impact on quality of
life. For example, a cross-sectional study of 1000 patients
with established RA found that 80% of patients reported
current foot problems and 71% reported difficulty in
walking due to problems with their feet [18]. The preva-
lence of foot joint involvement did not differ between
those in receipt of biological therapy (31%) and naïve
patients. Highly prevalent features including pain history
(90%), stiffness (77%), numbness (79%), and swelling
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Page 3 of 10(39%) have been reported in recent UK cohorts; and foot
deformity (82-86%) and skin pressure lesions (79%) in
Colombian and New Zealand cohorts [20,33,34]. Ulti-
mately, foot-disease impacts negatively on health related
quality of life [35].
Non-pharmacological interventions for foot disease in 
early RA: evidence and guidelines
There is emerging evidence to suggest that multidisci-
plinary team care of patients with RA, including podiatry
input, is effective in both inpatient and outpatient set-
tings [36]. The specific contribution of podiatry may be
unclear and difficult to separate as interventions such as
insoles, splints and orthoses can be provided by other
means, for example by an orthotist, physiotherapist or
occupational therapist or bought over-the-counter by the
patient. There is however a paucity of evidence for podia-
try-led specialised foot care in early RA [36,37]. Only one
randomised controlled trial of foot orthoses in relatively
early disease has been published indicating that cust-
omised rigid foot orthoses, designed to control correct-
able rearfoot deformity and off-load painful joints, were
more effective than standard orthoses prescribed under
medical care for reducing foot pain and disability and
restoring function [38,39]. This work has informed
expert-led recommendations of several European groups
[37,40]. For example, Gossec et al (2009) suggest that
metatarsal pain and/or foot alignment abnormalities
should be looked for regularly and that appropriate
insoles should be prescribed if needed [37]. Forestier et al
(2009) provide a disease-activity/staged non-pharmaco-
logical treatment strategy in which corrective orthoses
are recommended after resolution of a flare, to restore
functional range of motion and correct the level of physi-
cal activity [40]. In this protocol, preventative plantar
insoles are recommended in stable early RA as part of a
strategy to enable patients to accept their disease and pre-
vent functional deterioration.
Despite this obvious lack of evidence, recommenda-
tions for foot care feature in many UK and European
guidelines. These are summarised in Tables 1 and 2 for
both early and established disease. Various recommenda-
tions are made for inclusion of podiatrists in the multidis-
ciplinary care team, access to foot care, assessment and
review, and various interventions including insoles,
orthoses and footwear. However the level of supporting
evidence is low, mainly at the 'good clinical practice' and
'expert opinion' agreement level. No reference to special-
ist podiatry assessment or extended scope practice could
be found.
A new paradigm for podiatry in early RA
What new opportunities do recent paradigm shifts in the
management of early RA offer podiatrists? Evidence pre-
sented earlier indicates that active foot disease persists in
many patients despite recent treatment advances. More-
over, access to biological therapy is variable, there are
practical challenges to undertaking DAS28 monitoring in
routine practice, and the required changes to service pro-
vision to accommodate new care pathways are barriers in
translating evidence to practice [17,41,42]. Consequently,
in clinical practice remission rates are around 20%
depending on which criteria are used [43,44]. This evi-
dence, combined with current guidelines and good clini-
cal practice, indicates the need for ongoing
multidisciplinary team care, including podiatry, in early
RA.
Local development of this paradigm is based on experi-
ence from an academic-clinical partnership initiative in
Glasgow, UK. Support for specialist podiatry training and
professional development, clinical practice, and research
and audit are jointly provided by academic rheumatol-
ogy/podiatry units at The University of Glasgow and
Glasgow Caledonian University in conjunction with
National Health Service clinicians. This model is expand-
ing in Scotland with knowledge transfer facilitated
through the Podiatry Practice Development Group for
Rheumatology, a National Health Services Quality
Improvement Scotland Health Board network initiative
for allied health professions. Key aspects of the paradigm
include:
Early detection - widespread dissemination and uptake of 
referral guidelines
The necessity to obtain specialist referral to guarantee
early diagnosis and rapid treatment is evidenced by facts
that structural damage occurs early in RA, that joint
destruction increases the risk of irreversible disability,
and that early introduction of most treatment modalities
is associated with improved clinical response. The impor-
tance of clinical examination cannot be overlooked. Sim-
ple tests such as the MTP squeeze test are highly
predictive of persistent erosive arthritis (outcome) and
HAQ disability [33,45]. Recognising this, Emery and col-
leagues (2002) developed an early referral recommenda-
tion tool for primary care doctors (Appendix 1) [46].
Given the high prevalence of MTP joint involvement at
onset, podiatrists should be aware of these guidelines
when encountering patients with forefoot pain. Such
patients can reach podiatrists through a number of refer-
ral routes with an initial diagnosis of mechanically-
related metatarsalgia. The algorithm is easy to under-
stand and apply and should be widely disseminated
among podiatrists.
Therefore, under this new paradigm we propose to
increase the knowledge and understanding of early RA,
including the mandate for early recognition and treat-
ment. The early referral algorithm proposed by Emery et
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Table 1: Guidelines and recommendations for foot related non-pharmacological interventions in early rheumatoid arthritis.
Scottish Intercollegiate 
Guidelines Network 
Management of early 
rheumatoid arthritis [69]
Clinical practice 
guidelines for the use of 
non-pharmacological 
treatments in early 
rheumatoid arthritis [37]
British Society for Rheumatology 
and British Health Professionals in 
Rheumatology Guideline for the 
management of rheumatoid 
arthritis (the first 2 years) [70]
European League 
Against Rheumatism 
recommendations for 
the management of 
early arthritis [71]
Multidisciplinary 
guidelines for the 
management of early 
rheumatoid arthritis 
[72]
Multidisciplinary 
team care
Podiatry is part of the 
multidisciplinary team
Podiatry is part of the 
multidisciplinary team
Full-time dedicated podiatrist 
specialising in rheumatology is 
essential
Podiatry is part of the 
multidisciplinary team
Access to foot 
health care
'Good practice' to offer all 
patients with early RA a 
podiatry referral
Access to podiatry should be 
available according to patient need
Podiatry services should provide 
specific and dedicated service for 
diagnosis, assessment and 
management of foot problems 
associated with RA
Timely intervention for acute 
problems is important
Foot care can relieve 
pain, maintain function 
and improve quality of 
life
Foot Health 
Assessment/
Review
Metatarsal pain and/or 
foot alignment 
abnormalities should be 
looked for regularly
Annual foot review/assessment is 
recommended for patients at risk of 
developing serious complications in 
order to detect problems early
Appropriate lower limb assessment 
for vascular and neurological status is 
needed
Assessment of lower limb mechanics 
and foot pressures should occur
Annual foot review is 
recommended for 
patients at risk of 
developing 
complications
Orthoses/
Insoles/Splints
Some evidence for the 
efficacy of foot orthoses 
for comfort, and stride 
speed and length
Appropriate insoles 
should be prescribed if 
needed
Orthoses are an important and 
effective intervention in RA
Use of orthoses has 
shown short term relief of 
pain only, rather than an 
effect on disease activity.
Joint protection 
included-orthoses not 
specifically mentioned
Therapeutic 
footwear
Appropriate footwear for 
comfort, mobility, and 
stability is well recognised 
in clinical practice but little 
available evidence
There should be a provision of 
specialist footwear if needed
arthritis.
ritish Society for 
heumatology and 
ritish Health 
rofessionals in 
heumatology 
uideline for the 
anagement of 
heumatoid arthritis 
after the first 2 
ears) [77]
Clinical Practice 
Guidelines for non-drug 
treatment (excluding 
surgery) in rheumatoid 
arthritis [40]
Every patient with RA 
should be informed of the 
rules of foot hygiene and 
of potential benefit of 
referral to a podiatrist
A podiatrist should be 
consulted to treat nail 
anomalies and 
hyperkeratoses on the 
feet of patients with RA
Feet, footwear and 
orthoses should be 
regularly examined e
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Table 2: Guidelines and recommendations for foot related non-pharmacological interventions in established rheumatoid 
American College 
of Rheumatology 
Subcommittee on 
rheumatoid 
arthritis 
guidelines for the 
management of 
rheumatoid 
arthritis [73]
Arthritis and 
Musculoskeletal 
Alliance Standards of 
care for people with 
inflammatory arthritis 
[74]
Podiatry Rheumatic Care Association Standards 
of care for people with musculoskeletal foot 
health problems [75]
National Institute 
for Health and 
Clinical Excellence 
Rheumatoid 
arthritis National 
clinical guideline 
for management 
and treatment in 
adults [76]
B
R
B
P
R
G
m
r
(
y
Multidisciplinary 
team care
People with inflammatory 
arthritis should have 
ongoing access to local 
multidisciplinary team
Podiatrists are part of the 
multidisciplinary team.
Early referral for surgical opinion if required
Access to foot 
health care
All people with a sudden 
'flare-up in their condition 
should have direct access 
to specialist advice and 
the option for early review 
with the appropriate 
multidisciplinary team 
member
Timely access to foot health care - diagnosis, 
assessment and management
Adequate information/education should be given 
for self-management and signs/symptoms of 
deterioration in foot health and need to access 
specialist help promptly
All patients with RA 
and foot problems 
should have access 
to a podiatrist
Foot health 
assessment/
review
Foot health care providers must understand the 
consequences of systemic disease on the feet and 
be able to identify warning signs that require timely 
referral to specialist medical care
Musculoskeletal foot health assessment should 
include: General health; Foot health; Systemic 
factors; Lifestyle/Social factors; Pain management; 
Need for other assessments as required
Foot health assessment should occur within 3 
months of diagnosis - doesn't have to be done by 
foot health specialist
All patients with RA 
and foot problems 
should have access 
to a podiatrist for 
assessment and 
periodic review of 
their foot health 
needsW
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w Annual review of foot health needs are desirable - 
doesn't have to be done by foot health specialist
Where there is substantial change (better/worse) in 
disease activity, foot health should be reviewed
soles 
tic 
uld be 
ll 
A if 
Limited evidence for 
the use of foot 
orthoses - no 
consensus regarding 
choice of orthoses but 
reduction of pain and 
improved function of 
the foot are reported
Customised orthotic 
insoles are recommended 
in the case of weight-
bearing pain or static foot 
problems
Customised toe splints 
may be preventive, 
corrective or palliative to 
enable the wearing of 
shoes
Orthoses should be 
regularly examined
Semi-rigid orthotic 
supportive shoes can 
be effective for 
metatarsalgia - 
reduction in pain, 
disability, and 
improvement in 
activity as measured 
by the Foot Function 
Index have been 
reported
Patients should be 
advised about footwear
Footwear should be 
regularly examined
Extra-width off-the-shelf 
or therapeutic shoes 
thermoformed on the 
patient's foot are 
recommended when the 
feet are deformed and 
painful, or if it is difficult to 
put on shoes - such shoes 
reduce pain on walking 
and improve functional 
capacity
Off-the-shelf therapeutic 
thermoformed shoes for 
prolonged use are 
indicated when other 
types of footwear have 
failed
Palliative customized 
therapeutic shoes may be 
prescribed when the feet 
are seriously affected
atoid arthritis. (Continued)
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Orthoses/Insoles/
Splints
Non-
pharmacological 
treatment 
recommendations 
include joint 
protection but do 
not specifically 
mention orthoses
Functional in
and therapeu
footwear sho
available to a
people with R
indicated
Therapeutic 
footwear
Table 2: Guidelines and recommendations for foot related non-pharmacological interventions in established rheum
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Page 7 of 10al (2002) should be brought to the attention of all podia-
trists utilising national networks for dissemination and
training [46].
Targeted therapy - aggressive management of residual foot 
disease
Recommendations for podiatry/foot care in early RA
places an emphasis on access, annual review for those at
risk of developing foot complications and timely inter-
ventions (Table 1). Currently, definition of need, risk, and
timeliness are poorly understood. A pragmatic approach
may be to identify three groups of patients. Firstly those
with low disease activity (by DAS28) who have residual
disease activity in the foot with associated impairment
and disability. Case identification can be facilitated by
raising awareness among the rheumatology multidisci-
plinary care team, including training sessions on foot
problems, examination and management. Red flag condi-
tions should be prioritised e.g., tibialis posterior tendi-
nopathy with early flat-footedness, persistent synovitis in
any of the tarsus joints and persistent, non-responsive
and symptomatic forefoot disease despite low disease
state/remission. Further work is required before evidence
based recommendations can be made for routine screen-
ing of all early RA patients. The second group are those
with medium to high disease states where personalised
non-pharmacological interventions are undertaken based
on the presenting impairments to act in conjunction with
the systemic management. The third group are those
patients who fail to respond to biological therapy or are
ineligible and require close monitoring and care of active
foot joints.
In our opinion, targeted foot care should be delivered
by specialist podiatrists working in a multidisciplinary
clinic in both primary and secondary care. Extended
scope practice should include specialist training in diag-
nostic ultrasonography (using recognised training path-
ways, for example the PGcert in Medical Ultrasound);
corticosteroid injection therapies; non-pharmacological
interventions; gait analysis and rehabilitation. In the UK,
multidisciplinary foot clinics in rheumatology are not
new and they generally comprise of the podiatrist,
extended-scope physiotherapist and orthotist [47,48].
The rheumatologist, nurse specialist and orthopaedic
surgeon may be in attendance or a rapid referral pathway
developed. Evidence for such an approach is lacking, but
the area has been identified as a research priority.
A new paradigm for podiatrists focuses on combination
therapy targeted at inflammatory lesions and associated
mechanically-based impairments. This should include
ultrasound-guided aspirations, intra-articular and soft-
tissue corticosteroid injection therapy with cast immobil-
isation for residual lesions, and customised orthotics,
exercise and gait training for associated impairments.
Patients with evidence of joint instability and passively
correctable deformities should be targeted with highly
personalised orthotics, exploiting newer computer-aided
design and manufacture capabilities where available.
Orthotics treatment can be combined with exercises, gait
training, and therapeutic footwear, as well as joint protec-
tion and disease management advice and support. Minor
surgical procedures including nail surgery and cryosur-
gery are within the scope of practice for UK podiatrists.
Bone, joint and soft-tissue surgery is restricted to those
with advanced training and beyond the scope of this
review. Important training issues related to current
guidelines for RA patients in receipt of biological and
other immune system suppressing medication should be
provided during training [49]. UK podiatrists also have
limited prescribing rights and within the multidisci-
plinary clinic for early RA, access is generally limited to
analgesic, corticosteroid and antibiotic medicines.
Podiatrists should also be trained to recognise and
appropriately refer disease flare and other associated
complications. This includes, for example, skin and nail
infections of the feet in patients receiving biological ther-
apy as previously reported [50,51]. Podiatrists also pos-
sess core skills to assess and monitor peripheral vascular
and neurological diseases. Routine techniques such as
ankle-brachial pressure indices can be applied to screen
for potential risk factors for cardiovascular disease [52].
Under this paradigm we propose that specialist podiatry
roles are created, supported by high-level training and
mentorship, and that podiatrists actively engage in Early
Arthritis Clinics as part of the multidisciplinary team.
Accordingly patients should be targeted and treated
aggressively using injection therapy and personalised
Table 3: Candidate outcome for core and extended clinical 
foot datasets.
Outcome Domain
CORE
1. Swollen foot joint count Active disease
2. Tender foot joint count Joint destruction/soft-tissue 
damage
3. Foot Impact Scale-RA Foot impairment and 
disability
4. Structural Index Foot deformity
5. Radiographic erosions Joint destruction
EXTENDED
6. Ultrasound core set Active disease/joint 
destruction
Soft-tissue disease
7. Gait analysis
- spatiotemporal, plantar 
pressure, joint motion 
and forces
Functional
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where indicated.
Tight control of foot arthritis and disease monitoring
The concept of tight control can be applied for peripheral
joints as a central paradigm for podiatrists to aim for the
lowest foot disease state or remission. Care can then be
escalated or tapered based on monitoring foot disease
and related impairment and disability using a number of
clinical metrics. These are summarised in Table 3 as can-
didate outcomes for core and extended datasets. These
span foot-specific disease activity, joint destruction, and
impairment and disability, with a balance of objective and
patient-orientated outcomes. Swollen and tender joint
counts are based on the Ritchie Articular Index which
originally incorporated the tibio-talar, subtalar, midtarsal,
MTP and interphalangeal joints [53]. The Structural
Index is a semi-objective scale to measure foot deformity
and function. It works adequately in practice but requires
validation [54]. The Foot Function Index (FFI) and Foot
Impact Scale (FIS) for RA are well-validated RA specific
outcome tool for foot related impairment and disability
[55,56]. The psychometric properties of both instruments
currently make them the most appropriate outcome
instruments to determine treatment escalation or taper-
ing [57]. Routine monitoring by DAS28 has led to larger
numbers of patients reaching low disease state through
increased changes in DMARD treatment [58]. On that
basis use of the FFI and FIS must be promoted among
podiatrists to drive treatment change and provide objec-
tive treatment targets.
Radiographic erosions, scored using Sharp-van der
Heijde method should be reviewed during routine follow-
up. Within extended scope practice, B-Mode and power
Doppler ultrasound (US) is being increasingly used by
specialist podiatrists. The advantages, especially for
inflammatory foot disease are well established and the
clinical utility for podiatrists is extremely high. US per-
mits better identification of synovitis and erosions in foot
joints over conventional radiographs in early disease [59-
61]. US is superior to clinical examination for locating
and quantifying synovitis, erosions and tendinopathies
especially in complicated anatomical areas such as the
peri-talar region [31,62-65]. Moreover, US has been
shown to beneficially influence the planning of local cor-
ticosteroid injection therapy in the foot; to provide more
accurate needle tip placement and subsequent injection
as well as aspiration and infiltration of tendon sheaths,
joint spaces and bursae. It lessens procedural pain and it
leads to improved short-term efficacy [64,66,67]. Evi-
dence is emerging of good competency standards among
UK podiatrists undertaking US scanning techniques [68].
In an extended data set, and where access is available,
three-dimensional gait analysis provides the most objec-
tive way of capturing functional changes in the foot. It has
been successfully employed in early RA to detect subtle
but clinically important functional changes [24].
Past experience from multidisciplinary foot clinics in
rheumatology indicate that patients should be regularly
followed up until problems are resolved [47]. In early RA
patients this should constitute low foot disease state or
remission, with concomitant improvements in impair-
ment, related disability and quality of life. Early detection
and aggressive treatment within a therapeutic window of
opportunity when disability is potentially reversible is
critical.
Under this paradigm, we propose that podiatrists tightly
control foot arthritis using personalised treatment plans
which are agreed within the multidisciplinary team. Dis-
ease management should be escalated or tapered accord-
ing to defined criteria combining objective image-based
techniques and patient orientated outcomes.
Conclusions
Proposals contained within this commentary are predi-
cated upon major developments in the clinical under-
standing of RA and paradigm shifts concerning early
detection and treatment, tight control of disease and
monitoring, and the introduction of biological therapies.
However, despite these advances evidence indicates that
active disease in the foot is an ongoing problem in clinical
practice. A new paradigm of podiatry care can adopt
these advancements in early disease, exploiting the
extended scope practice capabilities and training oppor-
tunities available. To evidence the paradigm, UK podia-
trists are forming multi-centre research networks to
facilitate cohort and interventions studies. Studies are in
progress to understand disease mechanisms, to assess the
burden and impact of foot disease in early RA, to develop
a minimum foot core-set, to define foot disease remis-
sion, and to pilot interventions, outcomes and health eco-
nomic impact. These studies are building towards a
definitive trial of the clinical and cost-effectiveness of foot
care in early RA. If proven, the paradigm may be general-
isable to other forms of inflammatory, post-traumatic and
degenerative disorders in the musculoskeletal field as well
as a model for the management of neurologic induced
dysfunction, e.g., neuropathic ulceration and Charcot's
disease.
Appendixes
Appendix 1. Early referral guidelines for newly diag-
nosed rheumatoid arthritis (after Emery et al 2002) [46].
Rapid referral to a rheumatologist advised in the
event of clinical suspicion of RA, which may be sup-
ported by the presence of any of the following:
≥ 3 swollen joints
MTP/MCP involvement- Squeeze test positive
Morning stiffness of ≥ 30 minutes
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